New combo pill aims to supercharge weight loss in obesity trial
Disease control
Not yet recruiting
This study tests whether adding an experimental oral drug (ECC4703) to the existing weight-loss medication semaglutide helps adults with obesity lose more weight and reduce liver fat. About 160 participants will receive either the combination or a placebo for 20 weeks. The main g…
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC